fbpx

Research

Video Interview | KEBNI: Targeting capacity of 10,000 IMUs per year in 2025

Analys, Research

With another NLAW order to Saab from Finland of SEK 400m, KebNi is now targeting a production capacity of 10,000 IMUs by 2025 and expect...

Read More

QLUCORE: Important milestone passed on the road to a more individualized cancer care

Analys, Research

The progress in Q3’22/23 (Nov–Jan) continues to support the long term case we’re seeing in Qlucore, where the company aims to provide...

Read More

Interview | CRUNCHFISH: ”Simultaneous expansion of potential, presence, people, product and patent portfolio”

Analys, Research

On its mission to provide the same level of robustness to digital payments services as is required by other commercial and public goods...

Read More

BONZUN: Evolve to drive doubling of revenues in 2023

Analys, Research

After a comprehensive adjustment of business focus, balance sheet, costs and valuation in 2022, along with a recent restocking of the...

Read More

KEBNI: Great NLAW backdrop yet to translate to the KebNi share

Analys, Research

With another NLAW order, from Finland of SEK 400m, Saab’s delivery timeline support a revenue scenario for KebNi that exceeds its own...

Read More

MOTION DISPLAY: Strong start to 2023 sets the stage for an exciting year ahead

Analys, Research

As 2022 ended on a high note for Motion Display, with deals signed in the USA, Germany and Australia, there are reasons to believe that...

Read More

FREE2MOVE: Targets profitable growth as energy efficiency is rising on the agenda

Analys, Research

With a comprehensive offering to drastically improve the operating net for property owners, Free2Move looks to continue its strong growth...

Read More

SIMRIS ALG: Transforming to build an integrated multi-vertical microalgae and cyanobacteria company  

Analys, Research

Simris’ expanded objective to leverage the acquisition of Cyano Biotech in Q3’22, enter the high-value biopharma space and build a...

Read More

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More

AGTIRA: Looking to maintain momentum into 2023

Analys, Research

Agtira closed its books for 2022 reaching record high sales of 25.5 MSEK, an 80% increase compared to 2021. While the growth was strong, we...

Read More

For new research on growth stocks, sign up to our newsletter